Deals of Year Spotlight Financings and Collaboration
Tuesday, January 7, 2014
Posted by: Maria Thacker
ATLANTA, GA (January 8, 2014) --
Georgia Bio announced its 2014 Deals of the Year for pharmaceutical, biopharmaceutical
and medical device companies in two categories – private financing and public/private
collaboration – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions
by life sciences companies in Georgia such as financings, partnering agreements
and government grants that are significant to the state’s industry development.
Deals of the Year are awarded to one or more companies or institutions for the
most significant financial or commercial transactions closed from November 1,
2012-October 31, 2013. The recipients will receive their awards at the Georgia
Bio Annual Awards Dinner January 23, 6 pm to 9 pm, at Atlanta’s Fox Theater.
Arbor Pharmaceuticals, LLC
led by Ed Schutter, President and CEO, announced in September 2013 that Takeda
Pharmaceutical Company Limited and Arbor Pharmaceuticals Ireland Ltd., a
wholly-owned subsidiary of Arbor Pharmaceuticals, LLC have entered into a
license, development and commercialization agreement. The agreement will
provide Arbor with exclusive rights to market and sell EDARBI (azilsartan
medoxomil) and EDARBYCLOR (azilsartan medoxomil and chlorthalidone) in the U.S.
market. Dr. Brian Adams, Vice President of Business Development, led the Arbor
acquisition team. Arbor is a specialty pharmaceutical company headquartered in
Atlanta, Georgia and currently focused on the cardiovascular, pediatric and hospital
markets. The company intends to become a leading specialty pharmaceutical
company by actively licensing, developing and commercializing late-stage
products for specialty focused conditions. To learn more, visit http://www.arborpharma.com.
Clearside Biomedical Inc.
led by CEO Daniel White raised nearly $8 million from investors, including a
Japanese pharmaceutical company, as it prepares for late-stage trials on a
novel injection technique. The new
capital will help the company take the steroid — CLS1001 (triamcinolone
acetonide) — into Phase III clinical trials, and also help the company
investigate additional compounds. Based
in Alpharetta, Clearside is a clinical stage, ophthalmic pharmaceutical company
developing and commercializing targeted therapeutics for the treatment of sight
threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to
retinal blindness by delivering
therapeutics to the retina and choroid through the suprachoroidal space using a
proprietary microinjection dosage form. To learn more, visit http://clearsidebio.com/.
CorMatrix® Cardiovascular, Inc. led by Co-Founder,
CEO and Chairman David Camp, is a privately held medical device company
dedicated to innovative biomaterial devices that harness the body’s own innate
ability to repair damaged cardiovascular tissue. In October 2013, CorMatrix announced raising from
private investors $24.6 million in equity financing. Headquartered in Roswell,
Georgia, the Company is currently researching, developing and commercializing a
platform technology known as the CorMatrix ECM® for a variety of cardiovascular
indications. To date, the Company has received U.S. clearance and European
approval to market its ECM technology for three products: pericardial repair
and reconstruction, cardiac tissue repair, and carotid
artery repair. With significant patent
protection, CorMatrix is poised to successfully expand its current line of
products, including a planned clinical safety trial in Europe Q1 2014 with a
product designed to treat Heart Failure patients. To learn more, visit www.cormatrix.com.
EndoChoice, Inc. led
by founder and president, Mark Gilreath, announced in January 2013, a
trifecta of deals to expand the company. The Atlanta based company
acquired Peer Medical of Caesarea, Israel and RMS Endosckopie-Technik of
Hamburg, Germany while closing a $43 million fund-raising round led by Sequoia
Capital and its existing investors.
in Atlanta, EndoChoice is a medtech company focused on the manufacturing and
commercialization of platform technologies including devices, diagnostics,
infection control and endoscopic imaging for specialists treating a wide range
of gastrointestinal diseases. EndoChoice leverages its direct sales
organization to serve more than 2,000 customers in the United States and works
with 34 distribution partners world-wide. The Company was founded in 2008
and has rapidly developed a proprietary product portfolio, which includes the
revolutionary Full Spectrum Endoscopy™ System (Fuse™). 2013 marked the fourth
consecutive year EndoChoice was recognized as one of the fastest growing
companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com
Royal Philips and
Georgia Regents Health System, Georgia’s academic health system affiliated
with Georgia Regents University, signed a 15-year, $300+ million alliance in
June that shifts the focus towards increasingly patient-centered approaches to
care that will decrease costs while increasing quality, satisfaction, and
clinical outcomes. Inherent to this
model is the self-imposed pressure by the partners for more end-to-end patient
care solutions rather than the prototypical drive to sell more equipment.
embedded in the agreement are shared risks and rewards built around public
quality and cost measures. With the Affordable Care Act basing more care
provider payments on keeping patients healthier, it is incumbent upon the two
organizations to deliver positive, measurable, and sustainable results.
the first-of-its-kind delivery model in the United States, Philips will provide
GRHS with a comprehensive range of consulting services, advanced medical
technologies, and operational performance, planning, and maintenance services
with a pre-determined monthly payment.
Other leading companies,
executives, researchers and dedicated individuals will receive Georgia Bio
Awards for the following categories (listed alphabetically by award title):
Awards - Richard diMonda, BEE, MSBME, MBA; Judy M. Gantt M.Ed., Centers
for Disease Control and Prevention; Joseph M. Patti, Ph.D., Biota
Pharmaceuticals, Inc.; Todd Sherer, PhD, CLP, Emory University
Leader of the Year - Dana Fallaize, Emory University
Growth Awards – David Hartnett, Metro Atlanta Chamber; David Perryman,
Awards - Amy Baxter, MD, CEO, MMJ Labs; Ami Klin, Ph.D., Director, Marcus
of the Year Award - Representative Ben Watson (R-166)
Award - Merial LTD & the University of Georgia
of the Year - Julie A. Johnson, RN, MSN/MBA, Ed.S., Social Circle High
is the private, non-profit association whose members include pharmaceutical,
biotechnology and medical device companies, medical centers, universities and
research institutes, government groups and other business organizations
involved in the development of life sciences related products and services.
Credentialed members of the news media are invited to attend. Registration is
complimentary. Please contact Maria Thacker (404-920-2042; email@example.com).